At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Tamoxifen Citratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Estrogen Receptor Targeted Treatment of Non-Muscle Invasive Bladder Cancer With Tamoxifen.
In Brief
A Phase 2 clinical trial evaluating Tamoxifen Citrate for Bladder Cancer. Completed, enrolled 15 participants across 2 sites.
Detailed Summary
Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartApr 2015
Primary CompletionSep 2017
Study CompletionJun 2019
TodayJul 2026
First PostedJul 23, 2014
Enrollment StartApr 1, 2015
Primary CompletionSep 12, 2017
Study CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.9 years ago
Interventions
Tamoxifen Citratedrug
Single-center, two-stage phase-II clinical trial (Simon design)